Selective serotonin reuptake inhibitor. Discontinuation syndrome.
Based on emerging research findings, nurses are urged to become more aware of SSRI discontinuation syndrome. To ameliorate or avoid the associated symptoms, client education is recommended, and dosage tapering is encouraged whenever possible. Although the symptoms associated with discontinuation syndrome usually are mild, they may pose particular safety concerns for clients with co-occurring conditions. In these situations, precautions should be taken to prevent exacerbation of existing problems.
Finfgeld
Deborah L
DL
Sinclair School of Nursing, University of Missouri, Columbia, MO 65211, USA. finfgeldD@health.missouri.edu
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001007:Anxiety / Q000139:chemically induced*; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004244:Dizziness / Q000139:chemically induced*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009722:Nurse Practitioners; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects*; D010353:Patient Education as Topic; D011568:Psychiatric Nursing; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D016312:Treatment Refusal
D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors